Not recruiting
Breast cancer metastatic
Not recruitingStudy on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations
Registered drugNo placebo
Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations
Registered drugNo placebo
- Disease:Breast cancer metastatic
- Substances:AlpelisibFulvestrant+4
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:Unicancer
